Ratings Shandong Sanyuan Biotechnology Co.,Ltd.

Equities

301206

CNE100005774

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-06-03 pm EDT			5-day change	1st Jan Change
27.27 ^CNY	-1.05%		-2.88%	-5.57%

May. 22	Shandong Sanyuan Biotechnology Co.,Ltd. Announces Final Cash Dividend on A Shares for 2023, Payable on 29 May 2024	CI
Apr. 22	Shandong Sanyuan Biotechnology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 43.98 times its estimated earnings per share for the ongoing year.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Sector: Food Processing

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SHANDONG SANYUAN BIOTECHNOLOGY CO.,LTD.	-5.57%	762M		-
COSUMAR SA	-1.03%	1.84B		B-
SÃO MARTINHO S.A.	-9.14%	1.75B		C+
SHREE RENUKA SUGARS LIMITED	-16.22%	983M	-	C-
SHANDONG BAILONG CHUANGYUAN BIO-TECH CO., LTD.	+6.66%	1.04B		-
ADECOAGRO S.A.	-16.49%	963M		B
BALRAMPUR CHINI MILLS LIMITED	-6.10%	879M		B
TRIVENI ENGINEERING & INDUSTRIES LIMITED	-5.47%	800M		B-
HONGMIAN ZHIHUI SCIENCE AND TECHNOLOGY INNOVATION CO.,LTD.GUANGZHOU	-4.78%	758M	-	-
MITSUI DM SUGAR HOLDINGS CO., LTD.	+8.38%	679M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes